1. Home
  2. KOD vs NWN Comparison

KOD vs NWN Comparison

Compare KOD & NWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$38.49

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Northwest Natural Holding Company

NWN

Northwest Natural Holding Company

HOLD

Current Price

$49.66

Market Cap

2.1B

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOD
NWN
Founded
2009
1859
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Oil/Gas Transmission
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.1B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
KOD
NWN
Price
$38.49
$49.66
Analyst Decision
Buy
Buy
Analyst Count
7
3
Target Price
$35.43
$54.33
AVG Volume (30 Days)
868.6K
286.0K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
3.71%
EPS Growth
N/A
36.45
EPS
N/A
2.33
Revenue
N/A
$1,289,363,000.00
Revenue This Year
N/A
$11.37
Revenue Next Year
N/A
$4.46
P/E Ratio
N/A
$21.34
Revenue Growth
N/A
11.83
52 Week Low
$4.39
$39.29
52 Week High
$47.84
$55.99

Technical Indicators

Market Signals
Indicator
KOD
NWN
Relative Strength Index (RSI) 57.09 49.96
Support Level $21.82 $48.32
Resistance Level $46.72 $50.17
Average True Range (ATR) 2.77 1.08
MACD 0.61 0.05
Stochastic Oscillator 78.56 42.14

Price Performance

Historical Comparison
KOD
NWN

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

About NWN Northwest Natural Holding Company

Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.

Share on Social Networks: